Lung Cancer | Specialty

FDA Grants Atezolizumab Priority Review in Lung Cancer

April 11th 2016

The FDA has granted a priority review to atezolizumab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer who express PD-L1 and have progressed after a platinum-containing regimen.

Europe Expands Nivolumab Lung Cancer Approval

April 7th 2016

The European Commission has approved nivolumab (Opdivo) for the treatment of patients with nonsquamous non–small cell lung cancer, regardless of PD-L1 levels.

Immunotherapy Agents Could Impact All Settings in NSCLC

April 7th 2016

Edward Kim, MD, discusses the impact of nivolumab (Opdivo) and pembrolizumab (Keytruda) in non–small cell lung cancer, potential combinations, biomarkers, and ongoing research.

Immunotherapy Agents Preferred Second Choice in NSCLC, But Questions Remain

April 5th 2016

Sarah Goldberg, MD, MPH, discusses the efficacy of immunotherapies, PD-L1 as a biomarker, and how these therapies will continue to alter the treatment of patients with non–small cell lung cancer.

TKIs Dominate NCCN Update in EGFR+ NSCLC

April 2nd 2016

Testing for EGFR mutations should be routine in patients with non–small cell lung cancer. With the presence of an EGFR mutation TKIs are an appropriate treatment option across multiple lines of therapy, according to the latest update from the NCCN.

Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN Guidelines

April 2nd 2016

Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant NSCLC will be incorporated into NCCN guidelines.

Erlotinib Bests Gefitinib in Phase III NSCLC Study

March 29th 2016

Treatment with gefitinib failed to show noninferiority compared with erlotinib for patients with pretreated non–small cell lung cancer.

Dr. Heather Wakelee on What to Do When Resistance to EGFR TKIs Emerges

March 24th 2016

Heather Wakelee, MD associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses treating EGFR-mutant patients with lung cancer who are resistant to EGFR tyrosine kinase inhibitors (TKIs).

Combining and Sequencing Immunotherapies in NSCLC

March 18th 2016

Emerging Checkpoint Inhibitors for Lung Cancer

March 18th 2016

Immune-Related Response Criteria in NSCLC

March 18th 2016

Checkpoint Inhibitors in NSCLC

March 18th 2016

Less Common Mutations in Lung Adenocarcinoma

March 18th 2016

ALK-Positive Lung Cancer

March 18th 2016

Emerging Agents for Advanced EGFR+ Lung Cancer

March 18th 2016

Treatment of Relapsed EGFR-Mutant Adenocarcinoma

March 18th 2016

Upfront EGFR-Targeted Therapy

March 18th 2016

Second-Line Therapies for Non-Driver NSCLC

March 18th 2016

Chemotherapy for Advanced Lung Cancer

March 18th 2016

The Future of Biomarker Testing in Lung Cancer

March 18th 2016